The quest for enhanced visualization in medical diagnostics constantly drives innovation in contrast agent technology. For Magnetic Resonance Imaging (MRI), the development of stable and effective contrast agents is paramount, and DOTA (1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, CAS 60239-18-1) has emerged as a pivotal molecule in this area. Its superior chelating capabilities are what set it apart and make it a preferred choice for many leading contrast agents.

DOTA is a macrocyclic ligand, meaning its structure forms a ring that can tightly bind metal ions. Specifically, its four nitrogen atoms and four carboxylate groups create a cage-like structure that offers exceptional affinity and stability for paramagnetic ions like Gadolinium (Gd3+). This robust binding is crucial because free Gd3+ ions can be toxic. The macrocyclic nature of DOTA provides significantly higher thermodynamic stability and kinetic inertness compared to linear chelators, which are more prone to dissociating and releasing the metal ion. This means DOTA-based contrast agents offer a better safety profile and more reliable imaging results.

NINGBO INNO PHARMCHEM CO.,LTD. is committed to supplying the pharmaceutical industry with high-quality DOTA, a critical component for advanced MRI contrast agents. We ensure our DOTA, with a minimum purity of 98% and appearing as a white solid, meets the rigorous demands of this sector. Our competitive pricing and stable supply chain from China make us an ideal partner for manufacturers looking to purchase DOTA. By choosing NINGBO INNO PHARMCHEM, you are ensuring access to a reliable source of this essential pharmaceutical intermediate.

The molecular formula of DOTA (C16H28N4O8) and its molecular weight of 404.42 are key technical specifications that underscore its precise structure. Whether you are developing new contrast agents or ensuring the quality of existing ones, our DOTA can meet your needs. We invite you to contact us to learn more about our DOTA products and how we can support your critical research and development efforts in medical imaging.